CG Oncology shares climbed more than 9% in early trading on November 16 after the company said its experimental therapy cretostimogene reduced the risk of bladder cancer recurrence by 68% in a clinical trial. The stock reached $81.23, moving above a technical buy point at $80.97, as the result topped expectations discussed by analysts and investors.
Trial reports a 68% reduction in recurrence risk
The study involved patients with non-muscle-invasive bladder cancer who had undergone surgery to remove their tumors. They then received cretostimogene or no further treatment. CG Oncology said patients treated with the experimental therapy had a 68% lower risk of their cancer returning.
The company estimates that about 50,000 people in the United States have this type of bladder cancer and says there are currently no approved treatments for them. The limited treatment options make the trial relevant to assessments of cretostimogene’s clinical and commercial potential. However, the information released did not include the trial’s sample size, follow-up period or full efficacy data, leaving those details important to evaluating the result.
RBC analyst says the result beat expectations
RBC Capital Markets analyst Leonid Timashev said the outcome exceeded the roughly 30% reduction anticipated when the trial was designed, as well as the approximately 40% reduction investors had expected. Even among the most optimistic investor discussions, he said, a reduction of more than 50% was not widely anticipated.
Timashev also noted that the trial had experienced delays. He said the stronger-than-expected performance of cretostimogene could help explain the timing, rather than a problem with the trial itself. No further details were provided on the duration or cause of the delay.
Safety and comparison with Inlexzo remain in focus
Timashev described the safety profile as clear and said no patients stopped treatment because of serious treatment-related side effects. He also cited the therapy’s non-chemotherapy approach as a potential competitive advantage over Johnson & Johnson’s Inlexzo. The available information did not include a head-to-head comparison, so that assessment remains the analyst’s view.
CG Oncology shares rose to $81.23 and crossed the $80.97 technical level as investors reacted to the trial result. The full clinical data, regulatory progress and whether the treatment’s effect holds up over a longer follow-up period remain key details to watch.